As of 2026-03-25, the Intrinsic Value of ALX Oncology Holdings Inc (ALXO) is -3.82 USD. This ALXO valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.04 USD, the upside of ALX Oncology Holdings Inc is -287.40%.
Based on its market price of 2.04 USD and our intrinsic valuation, ALX Oncology Holdings Inc (ALXO) is overvalued by 287.40%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.82 - -3.82 | -3.82 | -287.40% |
| P/E | (16.03) - (20.35) | (17.70) | -967.7% |
| DDM - Stable | (6.62) - (25.73) | (16.17) | -892.8% |
| DDM - Multi | (7.64) - (24.03) | (11.71) | -673.9% |
| Market Cap (mil) | 271.33 |
| Beta | 1.19 |
| Outstanding shares (mil) | 133.00 |
| Enterprise Value (mil) | 266.26 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.38% |
| Cost of Debt | 5.00% |
| WACC | 9.19% |